Head-to-head · Value Score
CoreAge Rx vs EdgeRx
Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, EdgeRx a 82. Here's who gives you the honest lower price — and where each one bites back.
CoreAge Rx
#1 · Grade A+ · Best Value
Est. first month
$149/mo
Save ~89% vs brand-nameEdgeRx
#53 · Grade B+ · Good Value
Est. first month
$229/mo
Save ~83% vs brand-nameThe verdict
CoreAge Rx takes it on Value Score, 93 to 82 — an est. $149/mo first month, with no teaser step-up baked in. EdgeRx isn't out of it: Men who want a straightforward, disclosed weekly-injectable price on either molecule and value knowing the pharmacy filling the script by name.
CoreAge Rx is also our overall #1 pick across the whole deals board — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | CoreAge Rx | EdgeRx |
|---|---|---|
| Value Score | 93 (A+) | 82 (B+) |
| Est. first month | $149/mo | $229/mo |
| Save vs brand-name | ~89% | ~83% |
| Semaglutide | $149/mo | $229/mo injectable |
| Tirzepatide | $349/mo | $299/mo injectable |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Flat — no step-up |
| Coverage | All 50 states | 46 states (excludes Arkansas, Indiana, Minnesota, South Carolina) |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
CoreAge Rx
The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.
Why it's a deal
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation — no lock-in
The fine print
- Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
EdgeRx
A men's-only protocol shop with flat, disclosed GLP-1 pricing, a named Chief Medical Advisor, and a named 503A compounding pharmacy — rare transparency for this tier of the board.
Why it's a deal
- Both molecules disclosed up front — semaglutide $229/mo, tirzepatide $299/mo, both once-weekly injectable with free shipping and no separate physician fee
- Named compounding pharmacy — Strive Pharmacy, 503A, operating since 2018 — most peers name none
- Named Chief Medical Advisor, Dr. John Starke, MD (ABEM board-certified)
- LegitScript certified
The fine print
- Men-only — not built for, or marketed to, women or other readers
- The named Chief Medical Advisor does not personally prescribe; the actual prescribing pool is unnamed licensed physicians
- Third-party lab testing is claimed but no specific lab is named
- Excludes Arkansas, Indiana, Minnesota, and South Carolina
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives board, and the same list for the other side is on alternatives to EdgeRx.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.